Skip to main content

Table 1 Best Response to HD IL-2

From: Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Type

Best Response

mM

(N = 40)

mRCC

(N = 17)

Initial Response

Complete Response

0 (0)

1 (6)

Partial Response

3 (8)

1 (6)

Stable Disease

20 (50)

9 (53)

Progressive Disease

17 (42)

6 (35)

Best Overall Response

Complete Response

4 (10)

2 (12)

Partial Response

5 (13)

2 (12)

Stable Disease

15 (37)

8 (47)

Progressive Disease

16 (40)

5 (29)